Edgewise Therapeutics Posts Data From Early-Stage Muscle Wasting Disease Trial
Sarepta's Duchenne Gene Therapy Shows Sustained Functional Improvements
Dyne Therapeutics Highlights New Preclinical Data For Duchenne Muscular Dystrophy Program
Capricor Stock Is Moving Higher As Duchenne Dystrophy Cell Therapy Slows Disease Progression By 71%
Duchenne Muscular Dystrophy Recent News
Solid Biosciences Stock Gains After Duchenne Dystrophy Gene Therapy Data
Sarepta's Stock Trading Higher As Duchenne Muscular Dystrophy Gene Therapy Shows Promise In Open-Label Study
Monthly Dosing Of Sarepta's Next-Gen Eteplirsen Can Potentially Achieve Over 10% Higher Dystrophin Expression In DMD Patients
Analysts: Roche Partnership Derisks Sarepta Investor Concerns
Sarepta, Roche Strike Gene Therapy Licensing Agreement Worth Up To $2.85B
Solid Biosciences Rips Higher On Positive Biomarker Data For DMD Drug
FDA Approves Sarepta's Second DMD Drug, Analyst Projects $500M-Plus Opportunity
Solid Biosciences Shares Crash To Record Low After FDA Places Gene Therapy Program On Hold
Sarepta Plunges After FDA Spurns Its Second Duchenne Muscular Dystrophy Drug
PTC Therapeutics Shares Spike After FDA Approves Drug For Younger Patients
Solid Biosciences Tanks After Reporting Adverse Event In Duchenne Muscular Dystrophy Trial
Why Wave Life Sciences's Valuation Is Falling By 25% (NASDAQ:WVE)
Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress
Analyst: Sarepta's DMD Gene Therapy Results 'Dramatic And Far Exceeding Expectations'
Sarepta Hits Record High As Duchenne Muscular Dystrophy Gene Therapy Yields Positive Results In Early-Stage Study
Turning Neutral: Morgan Stanley Downgrades Sarepta, Loxo Oncology, Global Blood Therapeutics
Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy
Goldman Sachs Gets Firm On Solid Biosciences
Sarepta's Beat And Raise Streak Continues
U.S. Approval Of PTC Therapeutics' Translarna 'Remains Unlikely'
Sarepta Marks A 'Very Important Day' For The DMD Community
Down 16% Over May, Has Sarepta Become A Cheap Takeout Target?
Exclusive: Capricor CEO Talks Exondys Competition